Oncothyreon Announces Presentation of PX-866 Clinical Data at American Association of Clinical Oncology Annual Meeting
10:20 EDT 2 Jun 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today
announced that data from two clinical trials of PX-866, a pan-isoform
phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today
at the American Society of Clinical O...
Other Sources for this Article
More From BioPortfolio on "Oncothyreon Announces Presentation of PX-866 Clinical Data at American Association of Clinical Oncology Annual Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
